Overview

Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma

Status:
Completed

Trial end date:
2003-07-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Antiviral drugs such as zidovudine and ganciclovir act against viruses and may be an effective treatment for HIV. Interleukin-2 may stimulate a person's white blood cells to kill lymphoma cells. Combining these treatments may be effective in treating AIDS-related primary central nervous system lymphoma. PURPOSE: Phase II trial to study the effectiveness of combining zidovudine, ganciclovir, and interleukin-2 in treating patients who have AIDS-related primary central nervous system lymphoma.

Phase:

Phase 2

Details

Lead Sponsor:

AIDS Malignancy Consortium

Collaborator:

National Cancer Institute (NCI)

Treatments:

Aldesleukin
Ganciclovir
Ganciclovir triphosphate
Interleukin-2
Zidovudine